iPSCs were used to correct a deficiency in a 59-year-old female patient with frontotemporal dementia and parkinsonism who was carrying an R406W mutation in the microtubule-associated protein tau (MAPT) gene. This evidence concerns the gene MAPT and Parkinson disease.